UroGen Pharma (URGN) Common Equity (2016 - 2026)
UroGen Pharma's (URGN) quarterly Common Equity came in at -$124.3 million in Q1 2026, down 167.45% YoY from $184.2 million in Q1 2025, and down 17.8% on a QoQ basis from -$105.5 million in Q4 2025.
UroGen Pharma (URGN) Common Equity (2016 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 11 years of Common Equity data on file, last reported at -$124.3 million in Q1 2026.
- Quarterly Common Equity fell 167.45% year-over-year to -$124.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$124.3 million (down 167.45% YoY) and the FY2025 annual result came in at -$105.5 million, down 1098.16% from the prior year.
- Common Equity retreated to -$124.3 million in Q1 2026, from -$105.5 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $30.3 million in Q2 2024 to a low of -$138.4 million in Q2 2023.
- A 5-year average of -$61.8 million and a median of -$63.3 million in 2022 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity slumped 1162.18% — and 2024, when it jumped 160.76%.
- Tracing URGN's Common Equity over 5 years: stood at -$89.4 million in 2022, then gained by 27.02% to -$65.2 million in 2023, then surged by 86.5% to -$8.8 million in 2024, then tumbled by 1098.16% to -$105.5 million in 2025, then slipped by 17.8% to -$124.3 million in 2026.
- The last three Common Equity figures came in at -$124.3 million (Q1 2026), -$105.5 million (Q4 2025), and -$115.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | -132.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -132.40 Mn |
| Mar 31, 2026 | -124.25 Mn |
| Dec 31, 2025 | -105.47 Mn |
| Sep 30, 2025 | -115.41 Mn |
| Jun 30, 2025 | -93.38 Mn |
| Mar 31, 2025 | -46.46 Mn |
| Dec 31, 2024 | -8.80 Mn |
| Sep 30, 2024 | 25.52 Mn |
| Jun 30, 2024 | 30.31 Mn |
| Mar 31, 2024 | -40.13 Mn |
| Dec 31, 2023 | -65.21 Mn |
| Sep 30, 2023 | -41.99 Mn |
| Jun 30, 2023 | -138.43 Mn |
| Mar 31, 2023 | -116.55 Mn |
| Dec 31, 2022 | -89.36 Mn |
| Sep 30, 2022 | -63.29 Mn |
| Jun 30, 2022 | -40.91 Mn |
| Mar 31, 2022 | -17.07 Mn |
| Dec 31, 2021 | 8.41 Mn |
| Sep 30, 2021 | 31.54 Mn |